Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on: Takeda announcing the presentation of real-world analyses for Entyvio (vedolizumab) in UC; InDex Pharmaceuticals announcing that it has enrolled the first patient in the Phase IIb CONDUCT trial for Kappaproct (cobitolimod); as well as Amgen announcing the European Commission approval of Amgevita (biosimilar adalimumab) in all available indications, including moderate-to-severe UC.
Reasons to Purchase
How do KOLs regard real-world analyses of Entyvio?
What potential threats could Entyvio face in the future?
What are KOL views on Kappaproct and how would this agent be used if approved?
What impact is Amgevita/Amjevita expected to have on the UC anti-TNF market?
According to KOLs, which anti-TNF biosimilar is expected to have the most success in UC?